J&J Outlines Pricing Transparency Plan, Will Others Follow?
Executive Summary
CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.
You may also be interested in...
Janssen's Drug Pricing Report Emphasizes Value Of Rebates
As political pressure on pricing continues to build, Janssen's first-ever transparency report notes average list price increase was 8.5% in 2016; annual pricing parties are no longer 'raves,' Raymond James & Associates says.
Janssen's Drug Pricing Report Emphasizes Value Of Rebates
As political pressure on pricing continues to build, Janssen's first-ever transparency report notes average list price increase was 8.5% in 2016; annual pricing parties are no longer 'raves,' Raymond James & Associates says.
Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit
Sanofi, Lilly and Novo are the targets, but if lawsuit gains traction, it could put entire PBM rebate model under legal scrutiny.